Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NSVEM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-HER2_vc-2
|
|||||
| Synonyms |
Anti-HER2-vc-1; anti-HER2 vc-1
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8.7
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
TLR7 agonist-2
|
Payload Info | ||||
| Therapeutic Target |
Toll-like receptor 7 (TLR7)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
The free sulfhydryl group obtained by the reduction of interchain cysteine is site-specific conjugated with maleimide, michael addition reaction.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.